Idorsia Ltd (SIX: IDIA) today announced that new data on aprocitentan, the first-and-only dual endothelin receptor antagonist ...

Adding Uptravi (selexipag) to standard-of-care PAH treatment within six months may reduce the risk of hospitalization, per a ...

G Camp, a startup incubation platform dedicated to bringing Taiwan's startups to the global stage, is leading eight exceptional Taiwanese startups to participate in Web Summit, Europe's largest and ...

HC Wainwright restated their buy rating on shares of Ligand Pharmaceuticals (NASDAQ:LGND – Free Report) in a report published ...

CG Cosmetic is transforming the world of cosmetic surgery by offering cutting-edge Gummy Bear Breast Implants at a game-changing all-inclusive price of $2,500. This groundbreaking offer is available ...

Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) have earned a consensus recommendation of “Buy” from the six brokerages that are covering the company, Marketbeat.com ...

Atrasentan is associated with a significant and clinically meaningful reduction in proteinuria compared with placebo in ...

Atrasentan previously demonstrated efficacy in the open-label AFFINITY basket trial, where it reduced the 24-hour urinary ...

The efficacy and safety of the selective endothelin type A receptor antagonist atrasentan in reducing proteinuria in patients with IgA nephropathy are incompletely understood. We are conducting a ...

One type of drug used to treat PAH is endothelin receptor antagonists. ERAs, as they are called, help keep blood vessels from narrowing. But these drugs don’t work as well for Black patients as ...

In testing responses to endothelin receptor antagonists, a type of therapy for PAH, women and white people were shown to respond more significantly to the treatment than men or Black people.

DOI: 10.1038/s41556-024-01524-6 Next came contraction, controlled by smooth muscle cells in the outer follicle layer, possibly regulated by progesterone and endothelin signaling. Inhibition of ...